Evaxion A/S (EVAX) vs Genenta Science S.p.A. (SAEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Genenta Science S.p.A. is the larger company by market cap ($24.5 million vs $20.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | SAEN |
|---|---|---|
| Share price | $2.25 | $0.5074 |
| Market cap | $20.75M | $24.47M |
| 1-day change | +10.84% | -9.39% |
| YTD return | -52.83% | — |
| 1-year return | -56.56% | — |
| 5-year return | -99.07% | — |
| EPS (TTM) | $-1.00 | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.53M | — |
| Revenue growth (YoY) | +125.12% | — |
| Net income (latest FY) | $-7.71M | — |
| Operating margin | -122.66% | — |
| Net margin | -102.38% | — |
| 52-week high | $6.92 | $2.58 |
| 52-week low | $2.03 | $0.50 |
| Distance from 52-week high | -67.49% | -80.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +400.00% | — |
| Average volume | 85.00K | 85.01K |
| Shares outstanding | 9.22M | 48.22M |
| Employees | 46 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About Genenta Science S.p.A.
SAEN stock →Genenta Science S.p.A. operates as a strategic consolidator that focuses on acquiring ownership of privately held companies operating in Italian national-security-regulated sectors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 9 employees
EVAX vs SAEN FAQ
Which is bigger, Evaxion A/S or Genenta Science S.p.A.?
Genenta Science S.p.A. (SAEN) is larger, with a market capitalization of $24.47M compared with $20.75M for Evaxion A/S (EVAX).
Are Evaxion A/S and Genenta Science S.p.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.